Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016

Los Angeles, California, November 28, 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”) develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, is being developed as potentially the first FDA-approved treatment for lactose intolerance. The Company announced today that it will be […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update

LOS ANGELES (November 7, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the third quarter ending September 30, 2016. Recent Highlights Completed last patient dosing […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock

Los Angeles, California, October 26, 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the pricing of an underwritten public offering of 2,127,660 shares of its […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Los Angeles, California, October 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced that it intends to offer for sale shares of its common stock in […]

Leave Your Comments »

Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES (October 17, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum

LOS ANGELES (October 5, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum & Panel on […]

Leave Your Comments »

Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance

LOS ANGELES (August 15, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it has completed patient enrollment on schedule for its Phase 2b/3 clinical trial of its investigational compound RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

 Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update  LOS ANGELES (August 8, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the […]

Leave Your Comments »

Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28

Patent covers methods for treating symptoms associated with lactose intolerance and improving gastrointestinal health LOS ANGELES (June 28, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it recently has been issued […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

LOS ANGELES (March 21, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2015. 2015 and Recent Operational […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD